NCT02704104View on ClinicalTrials.gov

Safety and Performance Evaluation of the Topical Hemostatic Device (AC5™) Following Excision of Skin Lesions

NACompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Skin Neoplasms
Interventions
DEVICE

AC5 Topical Hemostatic Device

Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient

Trial Locations (1)

Unknown

University College Hospital, Galway

Sponsors

Lead Sponsor

Arch Therapeutics
All Listed Sponsors
lead

Arch Therapeutics

INDUSTRY

NCT02704104 - Safety and Performance Evaluation of the Topical Hemostatic Device (AC5™) Following Excision of Skin Lesions | Biotech Hunter | Biotech Hunter